Roesel Martin, Gutfleisch Matthias, Heinz Carsten, Heimes Britta, Zurek-Imhoff Beatrix, Heiligenhaus Arnd
Department of Ophthalmology, St. Franziskus Hospital, University Duisburg-Essen, DE-48145 Münster, Germany.
Ophthalmic Res. 2009;42(2):81-6. doi: 10.1159/000220600. Epub 2009 May 27.
To compare the effect of orbital floor (OFTA) or intravitreal (IVTA) administration of triamcinolone acetonide on visual acuity and chronic cystoid macular edema (CME) in patients with uveitis.
Retrospective study of patients suffering from chronic noninfectious uveitis in whom CME (n = 97) did not respond to systemic corticosteroids and/or immunosuppression combined with acetazolamide. Patients received a single injection of either IVTA (n = 48, group 1) or OFTA (n = 49, group 2). Best-corrected visual acuity, macular edema (fluorescein angiography), uveitis activity, ocular hypertension, and cataract formation were analyzed over the course of 1 year.
Improvement in visual acuity (> or = 2 lines, LogMAR) was noted in 50% (IVTA) and 34% (OFTA) after 3 months (p = 0.23), and in 18% (IVTA) and 20% (OFTA) after 12 months. CME improved in 100% (IVTA) and 76% (OFTA) of the eyes within the first month postoperatively (p = 0.36). Macular edema was reduced in 100% (group 1) and 20% (group 2) after 3 months (p < 0.01). At 1 year, cataract progression was noted in 68% (IVTA) and 27% (OFTA) (p < 0.01). Increased intraocular pressure (>21 mm Hg) was detected in 21% (IVTA) and 0% (OFTA) at 4 weeks (p < 0.01) after injection.
Uveitic CME and visual acuity not responding to systemic immunosuppression and acetazolamide may improve after an IVTA and OFTA injection. The effect is mostly transient. While the IVTA injections were more effective for improving CME, ocular hypertension and cataracts developed more often.
比较玻璃体内注射曲安奈德(IVTA)或眶底注射曲安奈德(OFTA)对葡萄膜炎患者视力及慢性黄斑囊样水肿(CME)的影响。
对慢性非感染性葡萄膜炎患者进行回顾性研究,这些患者的CME(n = 97)对全身使用皮质类固醇和/或免疫抑制联合乙酰唑胺无反应。患者接受单次IVTA注射(n = 48,第1组)或OFTA注射(n = 49,第2组)。在1年的时间里分析最佳矫正视力、黄斑水肿(荧光素血管造影)、葡萄膜炎活动度、眼压及白内障形成情况。
3个月后,50%(IVTA)和34%(OFTA)的患者视力提高(≥2行,LogMAR)(p = 0.23),12个月后分别为18%(IVTA)和20%(OFTA)。术后第1个月内,100%(IVTA)和76%(OFTA)的患眼CME得到改善(p = 0.36)。3个月后,100%(第1组)和20%(第2组)的黄斑水肿减轻(p < 0.01)。1年后,68%(IVTA)和27%(OFTA)出现白内障进展(p < 0.01)。注射后4周时,21%(IVTA)和0%(OFTA)检测到眼压升高(>21 mmHg)(p < 0.01)。
对全身免疫抑制和乙酰唑胺无反应的葡萄膜炎性CME和视力在IVTA和OFTA注射后可能改善。这种效果大多是短暂的。虽然IVTA注射对改善CME更有效,但眼压升高和白内障更常发生。